FDA Commissioner Scott Gottlieb reiterated over the weekend (Jan. 5 and 6) that the agency will not accept any new abbreviated new drug applications for generic drugs during the government shutdown, and said that funding to review some pending brand-drug and biologic applications will run out in about a month. If the shutdown stalemate continues, the pause in drug approvals could delay generic competition. “If FDA isn’t accepting any new applications and dates come up for the first generic filers,...